���构特征与受体作用机制 — Quick Reference

By Editorial Desk · published 2025-09-03 · last reviewed 2025-09-21 · News

Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Storage, Handling, and Analytical Verification

Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.

Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.

Semaglutide at a glance

Mechanism and Pharmacological Class

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Related pages on this site

• Scheduled report
• Automated comparison
• Material workbook
• Reliable update
• Automated reference
• Modern primer
• Modern collection
• Practical review

Molecular Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Supporting material

The city and the metropolitan area has a dense transport network. This solves the problem of a break between the lower town and the upper town and the two parts of the city are connected by long boulevards, winding roads, many stairs, a funicular and the Jenner tunnel. The CODAH transport network is called Lia and is operated by the Ocean Port Transport company (CTPO), a subsidiary of Veolia Transport. The overhaul of the bus network in 2008 helped to ensure a better service for all the towns in the metropolitan area. The CTPO operates a bus network consisting of 19 regular urban routes and six evening routes called the "Midnight Bus". The Le Havre urban area is served by 165 vehicles and 41 regular bus routes with an average of 100,000 passengers per day. From January 2011 there has been a regular shuttle service specific to the Industrial Zone and Port of Le Havre, thus adding to the cross-estuary service of VTNI. Since 1890 the funicular has provided a link between the upper town and the lower town in four minutes with a cable car. Le Havre had a tramway system from 1894 until it closed in 1957. More recently a new tramway system, with 23 stations and 13 km (8 mi) of route, was built, and opened on 12 December 2012. The first part of the line connects the beach to the station climbing to the upper town through a new tunnel near the Jenner tunnel then it splits into two: one link going to Mont-Gaillard, the other to Caucriauville.

Proteins can be engineered to improve the chance of successful protein crystallization. A common way is by trimming the recombinant construct to remove N- and C- terminal parts, which are frequently disordered or poorly structured ("high entropy"). Surface entropy reduction entails replacing surface residue clusters with high conformational entropy (usually lysine, glutamate, and glutamine) with alanines. In a similar vein, replacing lysine with arginine in bulk has proven useful. It is also possible to engineer in crystal contacts by mutating residues. An even more advanced method involves the use of "chaperone" proteins known to be more crystallizable. This can be achieved by designing a fusion protein consisting of the protein with unknown structure and a protein domain known to crystalize well. The interaction in question can also be intermolecular, for example between the candidate protein and some antibody Fab fragments selected to bind tightly to the protein, or between a candidate-maltose-binding protein (MBP) fusion and a protein specifically designed to bind MBP. Many methods for protein engineering require some forward knowledge of protein structure, either simply knowing what residues are surface or buried or knowing the full tertiary structure. Modern protein structure prediction tools are largely sufficient. It is also possible to predict the result of crystallization using these methods. Cystine residues on the surface tend to cause trouble for recombinant protein production by causing aggregation. They can be replaced with alanines.

Noteworthy side effects include dry mouth, headache, fatigue, dizziness, intermittent facial oedema, nausea, sleep disturbances (rarely sedation), asthenia, vasodilatation, and rarely, skin reactions.

=== Collagen === Collagen is the most abundant protein in mammals and is an essential molecule in the formation of bones, skin and other connective tissue. Different types of collagen have been found in all multicellular organisms, including sponges. It has been found that sponges do have a gene sequence coding for collagen type IV which is a diagnostic feature of the basal lamina. It has also been found that 29 types of collagen have been found to exist in humans. This vast group can further be divided into several families according to their primary structures and supramolecular organization. Among the many types of collagens, only the fibrillar and the basement membrane (type IV) collagens have been found in the sponges and cnidarians, which are the two earliest branching metazoan lineages. Studies have focused on the origin of fibrillar collagen molecules. In Sponges, there exist three clades of fibrillar molecules, A, B and C. It is proposed that only the B clade fibrillar collagens preserved their characteristic modular structure from sponge to human. In mammals, the fibrillar collagens involved in the formation of cross-striated fibrils are types I–III, V, and XI. Type II and type XI collagens compose the fibrils present in cartilage. These can be distinguished from collagens located in non-cartilaginous tissues, which include type I, III, and V collagens.

Sources: en.wikipedia.org

Notes from published material

=== Retinopathy of prematurity === Clinical work is at an earlier stage in the development of Iplex to treat Retinopathy of Prematurity (ROP). This disease, affecting an estimated 14,000 to 16,000 premature infants each year, causes the lack of development of the small blood vessels in the back of the eye leading to blindness in the majority of cases. A Phase I clinical study investigating Iplex as a treatment for ROP has been initiated at the University of Gothenburg in Sweden, in collaboration with scientists at the Harvard Medical School in the U.S. results of this study are expected by the end of 2007.

ketogenic amino acid Any amino acid that can be converted directly into acetyl-CoA, which can then be oxidized for energy or used as a precursor for many compounds containing ketone groups. This is in contrast to the glucogenic amino acids, which can be converted into glucose. In humans, seven of the 20 amino acids are ketogenic, though only leucine and lysine are exclusively ketogenic; the other five (phenylalanine, isoleucine, threonine, tryptophan, and tyrosine) are both ketogenic and glucogenic.

Kissinger told Nixon: "While we have a moral case for bombing North Vietnam when it does not accept our terms, it seems to be really stretching the point to bomb North Vietnam when it has accepted our terms and when South Vietnam has not". As expected, Tho refused to consider any of the 69 amendments, and on 13 December 1972, he left Paris for Hanoi after accusing the Americans of negotiating in bad faith. Kissinger, by this stage, was worked up into a state of fury after Tho walked out of the Paris talks and told Nixon: "They're just a bunch of shits. Tawdry, filthy shits. They make the Russians look good, compared to the way the Russians make the Chinese look good when it comes to negotiating in a responsible and decent way". The National Security Advisor now advised Nixon to bomb North Vietnam to make them "talk seriously".

Sources: en.wikipedia.org

Frequently asked questions